Baxter International: stocks, financial statements

Disable ads for free
Dividends News

Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

  • BAX Ticker
  • NYSE Exchange
  • 50,000 Employees
2 rated
  • $75.51, $-0.56 (-0.74%) Previous Close
  • 2,899,949 Previous Volume
  • $71.17 / $93.62 52 week low / high
  • -19.34% Percent off 52 week high
  • 2020-12-01 Updated
  • 1.23% Dividend Yield (trailing)
  • 1.30% Dividend Yield (forward)
  • 0 Public float
  • 510,818,398 Outstanding shares
  • 43.71 P/E
  • 38.86 B Market Cap
Disable ads for free

Financial statements — Baxter International

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
11B 11B 11B 10B 10B
Cost Of Revenue
6.5B 6.3B 6B 5.9B 5.9B
Gross Profit
4.9B 4.8B 4.6B 4.3B 4.1B
Research and Development
540M 620M 620M 540M 590M
Selling General and Admin
2.4B 2.4B 2.5B 2.6B 2.8B
Operating Expense
9.5B 9.4B 9.1B 9B 9.3B
Operating Income
1.9B 1.8B 1.5B 1.1B 690M
Other Income Expense Net
-940M -83M -270M 3.8B -260M
1.9B 1.8B 1.5B 1.1B 690M
Interest Income
110M 97M 82M 98M 100M
Pretax Income
970M 1.7B 1.2B 5B 430M
Income Tax
-41M 63M 490M -12M 35M
Minority Interest
10M 0 0 0 0
Net Income
1B 1.6B 720M 4.9B 970M
Net Income Basic
1B 1.6B 720M 4.9B 970M
19 ← 15 2019 2018 2017 2016 2015
Current cash
3.3B 1.8B 3.4B 2.8B 2.2B
Short term investments
1.9B 1.8B 1.8B 1.7B 1.7B
1.7B 1.7B 1.5B 1.4B 1.6B
Other current assets
620M 620M 600M 650M 1.1B
Current assets
7.5B 5.9B 7.3B 6.6B 12B
Long term investments
86M 41M
Property plant equipment
5.1B 4.5B 4.6B 4.3B 4.4B
3B 3B 3.1B 2.6B 2.7B
Intangible assets
1.5B 1.4B 1.4B 1.1B 1.3B
Other assets
130M 150M 190M 170M 230M
Total assets
18B 16B 17B 16B 21B
Accounts payable
890M 1B 920M 790M 720M
Current long term debt
320M 2M 3M 3M 810M
Other current liabilities
1.6B 1.7B 1.8B 1.8B 2B
Total current liabilities
3.2B 2.8B 2.8B 2.7B 5.8B
Long term debt
5.3B 3.5B 3.5B 2.8B 3.9B
Other liabilities
240M 160M 140M 1.7B 2.2B
Minority Interest
10M 0 0 0 0
Total Liabilities
10B 7.8B 8B 7.3B 12B
Common stock
510M 510M 540M 540M 550M
Retained earning
16B 16B 14B 14B 9.7B
Treasury stock
1.1M 960K 920K 1.6M 1.6M
Capital surplus
6B 5.9B 5.9B 6B 5.9B
Shareholder equity
7.9B 7.8B 9.1B 8.3B 8.8B
Net tangible assets
-1.1B -880M 320M 970M 1.3B
19 ← 15 2019 2018 2017 2016 2015
Net Income
1B 1.6B 720M 4.9B 970M
790M 780M 750M 750M 760M
Changes in receivables
-84M -19M -100M 40M
Changes in inventories
4M -200M 76M 80M -120M
Cash change
1.5B -1.6B 590M 590M -710M
Cash flow
2.1B 2.1B 1.8B 1.7B 1.6B
Capital expenditures
-700M -680M -630M -720M -910M
Investing activity other
Total investing cash flows
-1.1B -940M -1.3B -720M -1.8B
Dividends paid
-420M -380M -320M -270M -910M
Net borrowings
1.9B -5M 630M -56M 2.5B
Other financing cash flows
-48M -28M 310M 290M -2.2B
Cash flow financing
500M -2.6B 61M -320M -360M
Exchange rate effect
-5M -120M 5M -27M -200M
Disable ads for free
Disable ads for free